Tamiflu and Relenza receive US pandemic liability protections
This article was originally published in Scrip
Executive Summary
Roche and GlaxoSmithKlinewill be shielded from most US product liability claims stemming from use of their respective neuraminidase inhibitors Tamiflu (oseltamivir) and Relenza (zanamivir) during a human influenza pandemic emergency.